163 related articles for article (PubMed ID: 38081676)
21. MRI-based radiomics signature and clinical factor for predicting H3K27M mutation in pediatric high-grade gliomas located in the midline of the brain.
Wu C; Zheng H; Li J; Zhang Y; Duan S; Li Y; Wang D
Eur Radiol; 2022 Mar; 32(3):1813-1822. PubMed ID: 34655310
[TBL] [Abstract][Full Text] [Related]
22. Glioma grading prediction using multiparametric magnetic resonance imaging-based radiomics combined with proton magnetic resonance spectroscopy and diffusion tensor imaging.
Lin K; Cidan W; Qi Y; Wang X
Med Phys; 2022 Jul; 49(7):4419-4429. PubMed ID: 35366379
[TBL] [Abstract][Full Text] [Related]
23. Non-Invasive Prediction of Survival Time of Midline Glioma Patients Using Machine Learning on Multiparametric MRI Radiomics Features.
Deng DB; Liao YT; Zhou JF; Cheng LN; He P; Wu SN; Wang WS; Zhou Q
Front Neurol; 2022; 13():866274. PubMed ID: 35585843
[TBL] [Abstract][Full Text] [Related]
24. Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma.
Hohm A; Karremann M; Gielen GH; Pietsch T; Warmuth-Metz M; Vandergrift LA; Bison B; Stock A; Hoffmann M; Pham M; Kramm CM; Nowak J
Clin Neuroradiol; 2022 Mar; 32(1):249-258. PubMed ID: 34919158
[TBL] [Abstract][Full Text] [Related]
25. Multiparametric MRI-Based Radiomics Model for Predicting H3 K27M Mutant Status in Diffuse Midline Glioma: A Comparative Study Across Different Sequences and Machine Learning Techniques.
Guo W; She D; Xing Z; Lin X; Wang F; Song Y; Cao D
Front Oncol; 2022; 12():796583. PubMed ID: 35311083
[TBL] [Abstract][Full Text] [Related]
26. Exploring MRI Characteristics of Brain Diffuse Midline Gliomas With the H3 K27M Mutation Using Radiomics.
Li Q; Dong F; Jiang B; Zhang M
Front Oncol; 2021; 11():646267. PubMed ID: 34109112
[TBL] [Abstract][Full Text] [Related]
27. [Pediatric-Type Diffuse High-Grade Gliomas].
Natsumeda M
No Shinkei Geka; 2023 Sep; 51(5):876-883. PubMed ID: 37743339
[TBL] [Abstract][Full Text] [Related]
28. Multicenter clinical radiomics-integrated model based on [
Zhang L; Pan H; Liu Z; Gao J; Xu X; Wang L; Wang J; Tang Y; Cao X; Kan Y; Wen Z; Chen J; Huang D; Chen S; Li Y
Eur Radiol; 2023 Feb; 33(2):872-883. PubMed ID: 35984514
[TBL] [Abstract][Full Text] [Related]
29. Machine Learning-Based Multiparametric Magnetic Resonance Imaging Radiomics for Prediction of H3K27M Mutation in Midline Gliomas.
Kandemirli SG; Kocak B; Naganawa S; Ozturk K; Yip SSF; Chopra S; Rivetti L; Aldine AS; Jones K; Cayci Z; Moritani T; Sato TS
World Neurosurg; 2021 Jul; 151():e78-e85. PubMed ID: 33819703
[TBL] [Abstract][Full Text] [Related]
30. Multimodal MR imaging signatures to identify brain diffuse midline gliomas with H3 K27M mutation.
Su X; Liu Y; Wang H; Chen N; Sun H; Yang X; Wang W; Zhang S; Wan X; Tan Q; Yue Q; Gong Q
Cancer Med; 2022 Feb; 11(4):1048-1058. PubMed ID: 34953060
[TBL] [Abstract][Full Text] [Related]
31. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
32. Prediction of H3K27M-mutant brainstem glioma by amide proton transfer-weighted imaging and its derived radiomics.
Zhuo Z; Qu L; Zhang P; Duan Y; Cheng D; Xu X; Sun T; Ding J; Xie C; Liu X; Haller S; Barkhof F; Zhang L; Liu Y
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4426-4436. PubMed ID: 34131804
[TBL] [Abstract][Full Text] [Related]
33. Using radiomics based on multicenter magnetic resonance images to predict isocitrate dehydrogenase mutation status of gliomas.
Liu Y; Zheng Z; Wang Z; Qian X; Yao Z; Cheng C; Zhou Z; Gao F; Dai Y
Quant Imaging Med Surg; 2023 Apr; 13(4):2143-2155. PubMed ID: 37064376
[TBL] [Abstract][Full Text] [Related]
34. Fulminant hemorrhagic course of a thalamic H3 K27-altered diffuse midline glioma in an adult patient: illustrative case.
Poletti N; Marques LL; Deigendesch N; Soleman J; Mariani L; Guzman R; Rychen J
J Neurosurg Case Lessons; 2024 Jan; 7(4):. PubMed ID: 38252930
[TBL] [Abstract][Full Text] [Related]
35. Indolent presentation of a diffuse midline glioma, H3 K27-altered.
Damodharan S; Helgager J; Puccetti D
Childs Nerv Syst; 2023 Mar; 39(3):833-835. PubMed ID: 36094605
[TBL] [Abstract][Full Text] [Related]
36. Pediatric spinal cord diffuse midline glioma with H3 K27M-alteration with leptomeningeal dissemination: a rare case with intracranial hypertension onset and no spinal cord-related symptom.
Liu Y; Sun P; Zhou M; Du J; Zeng G
Childs Nerv Syst; 2023 Jun; 39(6):1663-1666. PubMed ID: 36759369
[TBL] [Abstract][Full Text] [Related]
37. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
Rodriguez D; Calmon R; Aliaga ES; Warren D; Warmuth-Metz M; Jones C; Mackay A; Varlet P; Le Deley MC; Hargrave D; Cañete A; Massimino M; Azizi AA; Saran F; Zahlmann G; Garcia J; Vassal G; Grill J; Peet A; Dineen RA; Morgan PS; Jaspan T
Radiology; 2022 Jul; 304(1):174-182. PubMed ID: 35412366
[TBL] [Abstract][Full Text] [Related]
38. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
[TBL] [Abstract][Full Text] [Related]
39. H3 K27-altered diffuse midline glioma in adults arising from atypical regions: Two case reports and literature review.
Sugii N; Ninomiya Y; Akimoto Y; Tsurubuchi T; Ishikawa E
Radiol Case Rep; 2024 Jan; 19(1):200-206. PubMed ID: 38028289
[TBL] [Abstract][Full Text] [Related]
40. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
